These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27798211)

  • 1. Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.
    Smolders EJ; Colbers EP; de Kanter CT; Velthoven-Graafland K; Drenth JP; Burger DM
    J Antimicrob Chemother; 2017 Feb; 72(2):486-489. PubMed ID: 27798211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
    Sevinsky H; Tao X; Wang R; Ravindran P; Sims K; Xu X; Jariwala N; Bertz R
    Antivir Ther; 2015; 20(5):493-500. PubMed ID: 25361436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
    Marzolini C; Gibbons S; Khoo S; Back D
    J Antimicrob Chemother; 2016 Jul; 71(7):1755-8. PubMed ID: 26945713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
    Elliot ER; Amara A; Pagani N; Else L; Moyle G; Schoolmeesters A; Higgs C; Khoo S; Boffito M
    J Antimicrob Chemother; 2017 Jul; 72(7):2035-2041. PubMed ID: 28407075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
    Gervasoni C; Riva A; Cozzi V; Capetti A; Rizzardini G; Clementi E; Cattaneo D
    J Antimicrob Chemother; 2017 Jun; 72(6):1842-1844. PubMed ID: 28333266
    [No Abstract]   [Full Text] [Related]  

  • 8. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
    Majeed SR; West S; Ling KH; Das M; Kearney BP
    Antivir Ther; 2019; 24(8):557-566. PubMed ID: 31933482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.
    Boffito M; Kurowski M; Kruse G; Hill A; Benzie AA; Nelson MR; Moyle GJ; Gazzard BG; Pozniak AL
    AIDS; 2004 Jun; 18(9):1291-7. PubMed ID: 15362661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.
    Momper JD; Wang J; Stek A; Shapiro DE; Powis KM; Paul ME; Badell ML; Browning R; Chakhtoura N; Denson K; Rungruengthanakit K; George K; Capparelli EV; Mirochnick M; Best BM;
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):303-309. PubMed ID: 34732682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy.
    Salama E; Eke AC; Best BM; Mirochnick M; Momper JD
    J Clin Pharmacol; 2020 Dec; 60(12):1537-1550. PubMed ID: 32798276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
    Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
    Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
    Estévez JA; Moltó J; Tuneu L; Cedeño S; Antonijoan RM; Mangues MA; Clotet B; Domingo P; Puntes M; Barbanoj MJ; Valle M
    J Antimicrob Chemother; 2012 Aug; 67(8):2013-9. PubMed ID: 22566588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
    Zhu L; Brüggemann RJ; Uy J; Colbers A; Hruska MW; Chung E; Sims K; Vakkalagadda B; Xu X; van Schaik RH; Burger DM; Bertz RJ
    J Clin Pharmacol; 2017 Feb; 57(2):235-246. PubMed ID: 27432796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
    Kakuda TN; Opsomer M; Timmers M; Iterbeke K; Van De Casteele T; Hillewaert V; Petrovic R; Hoetelmans RM
    J Clin Pharmacol; 2014 Aug; 54(8):949-57. PubMed ID: 24644095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.
    Nguyen T; McNicholl I; Custodio JM; Szwarcberg J; Piontkowsky D
    AIDS Rev; 2016; 18(2):101-11. PubMed ID: 27196356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
    Sherman EM; Worley MV; Unger NR; Gauthier TP; Schafer JJ
    Clin Ther; 2015 Sep; 37(9):1876-93. PubMed ID: 26319088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.